Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy

被引:145
作者
Agrawal, Amit [1 ]
Sharma, Barjesh Chander [1 ]
Sharma, Praveen [1 ]
Sarin, Shiv Kumar [1 ]
机构
[1] GB Pant Hosp, Dept Gastroenterol, New Delhi 110002, India
关键词
INTRAHEPATIC PORTOSYSTEMIC SHUNT; PROGNOSTIC-SIGNIFICANCE; IN-VITRO; DIAGNOSIS; METAANALYSIS; PREVALENCE; RIFAXIMIN; SURVIVAL; PLACEBO; TESTS;
D O I
10.1038/ajg.2012.113
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Lactulose is effective in secondary prophylaxis of hepatic encephalopathy (HE). Probiotics improves minimal hepatic encephalopathy (MHE), which predisposes to HE. No study has been conducted on the secondary prophylaxis of HE using probiotics. Our objective was to study the effects of lactulose and probiotics for secondary prophylaxis of HE. METHODS: Consecutive cirrhotic patients who had recovered from HE were randomized to receive lactulose (Gp-L, 30 ml three times per day), three capsules of probiotics (Gp-P) per day containing 112.5 billion viable lyophilized bacteria per capsule, or no therapy (Gp-N). All patients were assessed by psychometry (number connection test (NCT-A, B), figure connection test if illiterate (FCT-A, B), digit symbol test (DST), and block design test (BDT)), critical flicker frequency (CFF) test, and arterial ammonia at inclusion. The patients were followed up monthly. The primary end point was development of overt HE according to West Haven criteria or a follow-up of 12 months. RESULTS: Of 360 patients who recovered, 235 (65.2%) met the inclusion criteria (Gp-L, n=80; Gp-P, n=77; and Gp-N, n=78). In all, 38 patients (16.1%) were lost to follow-up and 77 patients developed HE (Gp-L, n=18; Gp-P, n=22; and Gp-N, n=37). There was a significant difference between Gp-L and Gp-N (P=0.001) and between Gp-P and Gp-N (P=0.02) but no difference between the Gp-L and Gp-P groups (P=0.349). The rate of readmission for causes other than HE (Gp-L, Gp-P, and Gp-N, 19: 21: 28; P=0.134) and deaths (Gp-L:Gp-P: Gp-N=13:11:16; P=0.56) in all three groups were similar. There was a high prevalence of abnormal psychometry test results (NCT-A, 71.5%; NCT-B, 69.2%; DST, 76.9%; and BDT, 85.2%), and FCT-A and -B were abnormal in 35 of 48 patients (72.7%). CFF was <38 Hz in 118 patients (50.2%). Upon multivariate analysis, recurrence of overt HE was significantly associated with two or more abnormal psychometric tests and arterial ammonia after the recovery of an episode of HE. CONCLUSIONS: Lactulose and probiotics are effective for secondary prophylaxis of HE in patients with cirrhosis.
引用
收藏
页码:1043 / 1050
页数:8
相关论文
共 29 条
[1]   Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials [J].
Als-Nielsen, B ;
Gluud, LL ;
Gluud, C .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7447) :1046-1050
[2]   Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients [J].
Amodio, P ;
Del Piccolo, F ;
Pettenò, E ;
Mapelli, D ;
Angeli, P ;
Iemmolo, R ;
Muraca, M ;
Musto, C ;
Gerunda, G ;
Rizzo, C ;
Merkel, C ;
Gatta, A .
JOURNAL OF HEPATOLOGY, 2001, 35 (01) :37-45
[3]   Probiotic yogurt for the treatment of minimal hepatic encephalopathy [J].
Bajaj, Jasmohan S. ;
Saeian, Kia ;
Christensen, Kenneth M. ;
Hafeezullah, Muhammad ;
Varma, Rajiv R. ;
Franco, Jose ;
Pleuss, Joan A. ;
Krakower, Glenn ;
Hoffmann, Raymond G. ;
Binion, David G. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (07) :1707-1715
[4]   Persistence of Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy [J].
Bajaj, Jasmohan S. ;
Schubert, Christine M. ;
Heuman, Douglas M. ;
Wade, James B. ;
Gibson, Douglas P. ;
Topaz, Allyne ;
Saeian, Kia ;
Hafeezullah, Muhammad ;
Bell, Debulon E. ;
Sterling, Richard K. ;
Stravitz, R. Todd ;
Luketic, Velimir ;
White, Melanie B. ;
Sanyal, Arun J. .
GASTROENTEROLOGY, 2010, 138 (07) :2332-2340
[5]   Rifaximin Treatment in Hepatic Encephalopathy [J].
Bass, Nathan M. ;
Mullen, Kevin D. ;
Sanyal, Arun ;
Poordad, Fred ;
Neff, Guy ;
Leevy, Carroll B. ;
Sigal, Samuel ;
Sheikh, Muhammad Y. ;
Beavers, Kimberly ;
Frederick, Todd ;
Teperman, Lewis ;
Hillebrand, Donald ;
Huang, Shirley ;
Merchant, Kunal ;
Shaw, Audrey ;
Bortey, Enoch ;
Forbes, William P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (12) :1071-1081
[6]   Prognostic significance of hepatic encephalopathy in patients with cirrhosis [J].
Bustamante, J ;
Rimola, A ;
Ventura, PJ ;
Navasa, M ;
Cirera, I ;
Reggiardo, V ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 1999, 30 (05) :890-895
[7]   LACTITOL IN TREATMENT OF CHRONIC HEPATIC-ENCEPHALOPATHY - A METAANALYSIS [J].
CAMMA, C ;
FIORELLO, F ;
TINE, F ;
MARCHESINI, G ;
FABBRI, A ;
PAGLIARO, L .
DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (05) :916-922
[8]   Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies [J].
D'Amico, G ;
Garcia-Tsao, G ;
Pagliaro, L .
JOURNAL OF HEPATOLOGY, 2006, 44 (01) :217-231
[9]   FIGURE CONNECTION TEST - A UNIVERSAL TEST FOR ASSESSMENT OF MENTAL STATE [J].
DHIMAN, RK ;
SARASWAT, VA ;
VERMA, M ;
NAIK, SR .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1995, 10 (01) :14-23
[10]   Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998 [J].
Ferenci, P ;
Lockwood, A ;
Mullen, K ;
Tarter, R ;
Weissenborn, K ;
Blei, AT .
HEPATOLOGY, 2002, 35 (03) :716-721